Q2 2026 saw 9% constant currency revenue growth to $125.8M, with On-X and stent grafts leading gains. Adjusted EBITDA rose to $26.4M, and FY26 guidance was reiterated for both revenue and EBITDA. Key milestones included FDA approvals, the Endospan acquisition, and strong clinical data.Original docu…
Medical device company Artivion NYSE:AORTwill be reporting earnings this Thursday after the bell. Here’s what to expect.Artivion met analysts’ revenue expectations last quarter, reporting revenues of $116.3 million, up 17.5% year on year. It was a softer quarter for the company, with a significant…
Artivion AORT recently secured FDA premarket approval (“PMA”) for its AMDS Hybrid Prosthesis to treat acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion. The approval removes the institutional review board (“IRB”) requirement tied to the device's previous Humanitaria…
ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"…
